Literature DB >> 12668053

Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists.

D Cervia1, P Zizzari, B Pavan, E Schuepbach, D Langenegger, D Hoyer, C Biondi, J Epelbaum, P Bagnoli.   

Abstract

The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) receptor subtypes (sst(1)-sst(5)), which are endogenously expressed in growth cells (GC cells), have not yet been elucidated, although there is evidence that sst(2) receptors are negatively coupled to cytosolic free Ca(2+) concentration ([Ca(2+)](i)) and adenosine 3,5'-cyclic monophosphate (cAMP) accumulation. In addition, both sst(1) and sst(2) receptors are negatively coupled to growth hormone (GH) secretion in GC cells. Here we report on studies concerning the expression, the pharmacology and the functional role of native SRIF receptors in GC cells with the use of five nonpeptidyl agonists, highly selective for each of the SRIF receptors. Radioligand binding studies show that sst(2) and sst(5) receptors are present at different relative densities, while the presence of sst(3) and sst(4) receptors appears to be negligible. The absence of sst(1) receptor binding was unexpected in view of sst(1) receptor functional effects on GH secretion. This suggests very efficient receptor-effector coupling of a low-density population of sst(1) receptors. Functionally, only sst(2) receptors are coupled to the inhibition of [Ca(2+)](i) and cAMP accumulation and the selective activation of sst(5) receptors facilitates the stimulation of adenylyl cyclase activity through G(i/o) proteins. This effect was not observed when sst(2) and sst(5) receptors were simultaneously activated, suggesting that there is a functional interaction between sst(2) and sst(5) receptors. In addition, sst(1), sst(2) and sst(5) receptor activation inhibits GH release, further indicating that SRIF can modulate GH secretion in GC cells through mechanisms both dependent and independent on [Ca(2+)](i) and cAMP-dependent pathways. The present data suggest SRIF-mediated functional effects in GC cells to be very diverse and provides compelling arguments to propose that multiple native SRIF receptors expressed in the same cells are not simply redundant, but contribute to marked signalling diversity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668053     DOI: 10.1016/s0028-3908(03)00031-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

2.  Somatostatin coupling to adenylyl cyclase activity in the mouse retina.

Authors:  Barbara Pavan; Sara Fiorini; Massimo Dal Monte; Laura Lunghi; Carla Biondi; Paola Bagnoli; Davide Cervia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-12       Impact factor: 3.000

3.  Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia.

Authors:  Massimo Dal Monte; Valentina Latina; Elena Cupisti; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-07       Impact factor: 3.000

Review 4.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

5.  Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Caroline Nunn; Dominique Fehlmann; Daniel Langenegger; Edi Schuepbach; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Authors:  Mark Kidd; Ignat Drozdov; Richard Joseph; Roswitha Pfragner; Michael Culler; Irv Modlin
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

7.  Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents.

Authors:  Jose Córdoba-Chacón; Manuel D Gahete; Mario Duran-Prado; Ana I Pozo-Salas; María M Malagón; F Gracia-Navarro; Rhonda D Kineman; Raul M Luque; Justo P Castaño
Journal:  Cell Mol Life Sci       Date:  2010-04       Impact factor: 9.261

8.  Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis.

Authors:  Anat Ben-Shlomo; Oxana Pichurin; Ramtin Khalafi; Cuiqi Zhou; Vera Chesnokova; Song-Guang Ren; Ning-Ai Liu; Shlomo Melmed
Journal:  Endocrinology       Date:  2013-05-21       Impact factor: 4.736

Review 9.  Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy.

Authors:  Elisabetta Catalani; Clara De Palma; Cristiana Perrotta; Davide Cervia
Journal:  Biomed Res Int       Date:  2017-05-16       Impact factor: 3.411

10.  Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly.

Authors:  Juan F Martín-Rodríguez; Jose L Muñoz-Bravo; Alejandro Ibañez-Costa; Laura Fernandez-Maza; Marcin Balcerzyk; Rocío Leal-Campanario; Raúl M Luque; Justo P Castaño; Eva Venegas-Moreno; Alfonso Soto-Moreno; Alfonso Leal-Cerro; David A Cano
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.